The global outsourced drug discovery market is expected to grow at a CAGR of 12.1 percent between 2019 and 2026.

Outsourcing is a strategy in which a pharmaceutical company hires a third party, such as a contract research organisation, to perform planned and ongoing activities such as drug discovery, preclinical development, and clinical research. Outsourcing is a collaboration between contract research organisations and the pharmaceutical, biotechnology, and chemical industries. Contract research organisations (CROs) handle nearly every aspect of drug discovery, including clinical data management, data entry and validation, safety and efficacy summaries, medicine and disease coding, quality and metric reporting, validation programming, statistical analysis plans and reports, and final study reports.


The global outsourced drug discovery market was valued at US$ 20.7 billion in 2017 and is expected to grow at a CAGR of 12.1 percent between 2019 and 2026.

Increasing number of drug discovery companies is expected to drive growth of the global outsourced drug discovery market

The growing number of new drug discovery companies is expected to drive the growth of the global outsourced drug discovery market. For example, in November 2018, Schrodinger, LLC partnered with Wuxi AppTec to launch Faxian Therapeutics (Headquarters – New York, U.S.). Faxian Therapeutics will improve health care needs by utilising Schrodinger, LLC's computational platform and WuXi's drug design and synthesis services.


Furthermore, rising drug discovery services are expected to propel the global outsourced drug discovery market forward. In April 2019, Eurofins Discovery Services, a contract research organisation, launched its new drug discovery service Discover. The new approach is beneficial to drug discovery research and preclinical development. As a result, the launch of drug discovery services is expected to support the growth of the global outsourced drug discovery market.

Global Outsourced Drug Discovery Market- Regional Analysis

Because of business expansion in this region, the North American outsourced drug discovery market is expected to account for the largest market share. For example, in January 2019, Lambda Therapeutic Research (Headquarters-India) acquired Novum Pharmaceutical Research Services, a U.S.-based pharmaceutical research firm. Lambda Therapeutic Research entered the US market with this acquisition.


Furthermore, due to increased merger and acquisition activity by key players in the region, Europe is expected to see significant growth in the global outsourced drug discovery market.Optimapharm, a clinical research organisation (CRO) in Europe, for example, acquired Denothex, a CRO, in February 2019 to strengthen its presence in the European market, particularly in France, Spain, Switzerland, and Italy. Denothex conducts all oncology clinical trials in Europe and Israel.


Due to the increased launch of IT infrastructure investment programmes (Trial Management and Monitoring Cloud Service Implementation Program) for clinical trial development, Asia Pacific is also expected to see significant growth in the global outsourced drug discovery market. For example, Novotech, a CRO, launched new Oracle Trial Management and Monitoring d Service Implementation Program (TMMCS) in Asia-Pacific.TMMCS helps to maintain centralized trial management database and clinical research associate productivity. TMMCS provides various benefits including better trial results, improved investigator relationship, and lower trial costs.

Comments

Popular posts from this blog

Better awareness among women is driving the growth of the Bath Bombs Market

The global eSIM market was valued at USD 253.8 million in 2017 and is expected to reach USD 978.3 million by 2023

The rapid rise of the industrial tape business is one of the major reasons driving the growth of the gaffers tape market.